Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.
Zhe XuZhuo-Miao YeYu-Kai TangDong-Feng DengQin ZhouMan FangYing-Ying ZhangXiang-Ping LiPublished in: Cancer medicine (2023)
Regardless of whether the price of sintilimab plus IBI305 and sorafenib is covered by Medicare, sintilimab plus IBI305 is unlikely to be cost-effective for first-line treatment of patients with unresectable HCC.